Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-20-294045
Filing Date
2020-11-16
Accepted
2020-11-16 09:01:13
Documents
34
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d24961d10q.htm 10-Q 253640
2 EX-31.1 d24961dex311.htm EX-31.1 6477
3 EX-31.2 d24961dex312.htm EX-31.2 6409
4 EX-32.1 d24961dex321.htm EX-32.1 2936
5 EX-32.2 d24961dex322.htm EX-32.2 3015
  Complete submission text file 0001193125-20-294045.txt   1468333

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT inti-20200930.xml EX-101.INS 174706
7 XBRL TAXONOMY EXTENSION SCHEMA inti-20200930.xsd EX-101.SCH 17949
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inti-20200930_cal.xml EX-101.CAL 16664
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inti-20200930_def.xml EX-101.DEF 100025
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE inti-20200930_lab.xml EX-101.LAB 160682
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inti-20200930_pre.xml EX-101.PRE 129338
Mailing Address 4830 W. KENNEDY BLVD. SUITE 600 TAMPA FL 33609
Business Address 4830 W. KENNEDY BLVD. SUITE 600 TAMPA FL 33609 (813) 766-2462
Inhibitor Therapeutics, Inc. (Filer) CIK: 0001042418 (see all company filings)

EIN.: 541641133 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13467 | Film No.: 201313959
SIC: 8731 Services-Commercial Physical & Biological Research